Pfizer delivered its Q2 print on July 28 and the stock rose — yet short sellers added positions aggressively in the same week, creating the week's defining tension.
The short interest story is the standout here. SI climbed 27% over the past week to reach 3.2% of the free float, reversing a month-long decline. That move is sharp enough to notice: from roughly 145 million shares short in mid-July to 184 million by July 28. The borrow market offers no friction for those trades — availability is extraordinarily loose at over 5,000%, meaning there are more than fifty shares available to lend for every one already borrowed. Cost to borrow has actually eased over the week, down 14% to 0.43%. Short sellers face no structural squeeze pressure whatsoever. They are simply rebuilding positions into a post-earnings bounce, not fighting a tight lending market.
Options positioning tells a more relaxed story than the short rebuild might suggest. The put/call ratio has drifted slightly below its 20-day average, reading 0.83 against a mean of 0.84 — marginally less defensive than usual, though the z-score of -1.08 puts the move within normal range. The 52-week PCR band runs from 0.64 to 1.05, and the current level sits comfortably in the middle. Options traders, unlike the short sellers, appear unbothered by the week's events.
The Street enters the post-earnings period still cautious but not outright negative. Analyst targets drifted lower through July — JPMorgan and BofA both trimmed while holding Neutral, and HSBC went further with an outright downgrade to Hold before the print. The consensus mean now sits near $28.75 against a current price of $25.25, implying around 14% upside on paper. Bulls cite the forward earnings recovery — the 12-month forward EPS growth rank scores in the 97th percentile of the universe, reflecting a dramatic uplift from a depressed post-pandemic base — as well as a high dividend score (93rd percentile). Bears focus on gross-to-net pressures on premium products like Vyndaqel and Ibrance, and on the broader post-COVID revenue reset that still has the stock roughly flat to down on the year. The EV/EBITDA multiple of 8.3x has crept up slightly over the past month, though it remains well within a range consistent with mature-pharma peers. Among correlated peers, BMY gained over 4% on the week, outpacing Pfizer's more modest 1.2% move — a reminder that the pharma peer group has continued to outrun PFE in the near term.
Institutional ownership offers context on the ownership base. BlackRock holds 8.7% of shares and added roughly 24 million shares through June 30, while State Street added modestly. The holder base is dominated by passive and semi-passive index capital — which means the short rebuild is almost certainly active-fund driven, not index rebalancing. Insider activity has been quiet since a small Chief Accounting Officer sale in early June; the cluster of executive sells in late February, including a modest transaction from CEO Albert Bourla, all carried low significance scores and appear routine in nature.
Pfizer's next earnings event is scheduled for August 4 — a week away — which makes the current short rebuild particularly interesting to watch: the last Q1 print produced a 0.87% one-day gain that faded to a 1.6% loss over the following five days, and whether the Q2 result follows a similar pattern will be the next data point that tests whether the rebuilding shorts are early or well-timed.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
